Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

CDE Granted LM-302 Breakthrough Therapy Designation for Claudin 18.2 positive GC/GEJ

  • 2023-11-23

  • Share:

November 3rd, 2023 - LaNova Medicines Ltd. announced that CDE has granted LM-302 (anti-CLDN18.2 ADC) Breakthrough Therapy Designation in October 2023. This designation is for the treatment of third-line and above Claudin 18.2-positive, locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma patients.